Place · Level 3

Niacin

NAD / NADP 两套代谢账户 · 从色氨酸也能来 · NAD+ 与长寿的新故事

Story path

1NAD / NADP two ledgersNAD / NADP two ledgers
2Tryptophan routeTryptophan route
3Pellagra: the 4 DsPellagra: the 4 Ds
4NAD+ aging and NMN/NRNAD+ aging and NMN/NR
5High-dose flush and risksHigh-dose flush and risks

Chapter 1

NAD / NADP two ledgers

Once B3 enters the body it contributes to the formation of NAD (nicotinamide adenine dinucleotide) and NADP. The chemical difference between them is a single phosphate group, but the biological roles are completely different:

NAD+ / NADH: catabolic-leaning. Collects electrons in the cycle (NADH) and feeds the respiratory chain to make . Also serves as substrate for sirtuins: A family of NAD⁺-powered enzymes involved in repair and 'longevity'-linked cellular upkeep. (deacetylases) and PARP (DNA repair)NADP+ / NADPH: anabolic and reductive defense. Fatty-acid synthesis, sterol synthesis, and the antioxidant system (glutathione recycling) all rely on NADPH for reducing power
A useful analogy: NAD is the 'power-transmission line', NADP is the 'power-storage and consumption side'. The two are not interchangeable — cells precisely maintain the NAD+/NADH and NADP+/NADPH ratios separately.

NAD+ consumers

NAD+ is not just an electron carrier — it's also the substrate that several enzymes permanently consume, splitting NAD+ apart without returning it. One by one:

PARP (poly-ADP-ribose polymerase) detects and repairs DNA damage by cleaving NAD+ into nicotinamide and ADP-ribose, attaching ADP-ribose to proteins around damaged DNA. Chronic DNA damage (UV, chemotherapy, aging) keeps PARP active, and the NAD+ pool falls.

Sirtuins (SIRT1–7) are NAD+-dependent deacetylases regulating metabolism, stress response, and aging. SIRT1 governs insulin signaling and lipid metabolism; SIRT3 is mitochondrial and regulates metabolic efficiency; SIRT6 suppresses oncogenes. Caloric restriction and regular exercise upregulate , which is part of the speculated longevity mechanism; 'resveratrol mimics CR' is partly based on SIRT1 activation, though the evidence is weak.

CD38 is a glycoprotein on the surface of immune cells (especially plasma cells and B cells); one molecule can consume thousands of NAD+. Aging and chronic inflammation upregulate CD38, making it a key driver of falling NAD+ in old age, and a target for 'CD38 inhibitors (78c, apigenin)' anti-aging research.

SARM1 is a neuronal NAD+-consuming enzyme activated after axonal injury; over-activation drives axonal degeneration. Chemotherapy-induced peripheral neuropathy and parts of ALS are SARM1-related.

So NAD+ should be viewed as a dynamic 'income vs expense' pool. Income comes from niacin, NR, NMN, and tryptophan, feeding into the NAD+ pool through synthesis; expenses are jointly set by PARP (DNA damage), CD38 (inflammation), SARM1 (nerve damage), and sirtuins (regulation).

In aging, expenses (PARP + CD38 + SARM1) rise while income falls, and the whole-body NAD+ pool drops roughly by half between ages 50 and 80.

This is exactly the foundation of the NMN/NR anti-aging logic — top up income to offset rising expense. But just topping up income without cutting expenses (no control of chronic inflammation, no UV protection, no DNA-damage prevention) isn't enough — the water flowing in can't fill a bucket with holes.

Open this on the map Watch the mechanism

Chapter 2

Tryptophan route

The body has a backup pathway: converting tryptophan (an essential amino acid) into niacin. The conversion efficiency is roughly 60 mg tryptophan → 1 mg niacin equivalent (NE).

This route requires several nutrients:

B2 (FAD): kynurenine hydroxylaseB6 (PLP): multiple stepsIron: indoleamine 2,3-dioxygenase (IDO)
Practical implication: with sufficient protein intake (especially tryptophan-rich meat, eggs, dairy), dependence on dietary niacin is relatively reduced. But relying purely on tryptophan is unreliable — pregnancy, infection, and certain drugs divert tryptophan into other pathways (e.g., kynurenine → inflammatory pathway).

Pellagra history: corn is low in tryptophan, and the niacin in corn is in a bound form that's poorly absorbed. Populations dependent on corn as a staple have historically been at high risk of niacin deficiency. Mexican nixtamalization (treating corn with limewater) releases the bound niacin — it never transferred to Europe, which is why pellagra epidemics swept there.

Tryptophan's three forks

Tryptophan (Trp) is an essential amino acid that can be partitioned into three fates inside the body, with the ratio set by the activity of different enzymes.

The first is protein synthesis, the default main line — Trp is translated directly into new protein, ~60–70% of total Trp.

The second is the serotonin (5-HT) and melatonin pathway: Trp is converted by TPH (tryptophan hydroxylase, with iron and BH4 as cofactors) into 5-HTP, then into serotonin and melatonin. This mainly happens in intestinal enterochromaffin cells (~90%) and brain neurons (~10%), accounting for 1–5% of total Trp.

The third is the kynurenine pathway leading to NAD+, which is directly relevant to B3: Trp is converted by IDO (indoleamine 2,3-dioxygenase) and hepatic TDO into kynurenine, then into quinolinic acid, and finally NAD+. This pathway is significantly upregulated by inflammation and stress (IFN-γ, , cortisol). Normally it accounts for 20–30% of total Trp, but can exceed 50% during inflammation.

This brings up an often-overlooked phenomenon — 'inflammation steals tryptophan'. Chronic inflammation (RA, IBD, COPD, depression, aging) upregulates IDO, diverting large amounts of Trp into the kynurenine pathway, leaving less raw material for 5-HT synthesis — this is one possible molecular basis of the 'depression + inflammation' link; the kynurenine pathway's intermediates (3-HK, QUIN) are also neurotoxic. This is called the kynurenine hypothesis of depression.

So depression is not just 'low 5-HT' — which path Trp is diverted into matters as well; for people with chronic inflammation, controlling inflammation may be just as important as simply supplementing tryptophan or 5-HTP. 5-HTP supplementation may help short-term in low-5-HT states, but co-use with antidepressants risks serotonin syndrome.

In practice: turkey, eggs, cheese, nuts, and seeds are relatively high in tryptophan (although 'turkey makes you sleepy' doesn't hold up on concentration grounds); the key to improving Trp status is not Trp supplementation but anti-inflammatory work, adequate protein, sleep, and regular exercise.

Open this on the map

Chapter 3

Pellagra: the 4 Ds

Severe B3 deficiency causes pellagra. The classic presentation is the four Ds:

Dermatitis: a symmetric rash on sun-exposed skin, with sharp bordersDiarrhea: intestinal mucosal injuryDementia: neurocognitive changeDeath: if left untreated
Skin damage is most pronounced in sun-exposed areas because sunlight accelerates NAD+ consumption (DNA damage activates PARP).

Pellagra reminds us of a basic fact: 'vitamin' is not a wellness-marketing word, it's a small molecule whose absence makes basic cellular physiology collapse — NAD+ is involved in essentially every redox reaction, and without it, cellular energy metabolism and DNA repair both fail.

Goldberger's epidemic

The story of pellagra in the American South is one of the most profound social-medicine cases in nutrition history.

From the 1900s to the 1920s, pellagra was epidemic in the US South, with 100,000+ cases per year, mortality 5–25%, mainly affecting poor farmers, textile workers, orphanages, and prisons. Mainstream medicine assumed it was an infectious disease (by analogy to leprosy).

Joseph Goldberger (1914–1929), a US Public Health Service physician, was confident in the 'dietary cause' hypothesis. He noticed two things: epidemiologically, wealthy families never developed it, while poor Southern diets centered on corn + molasses + salt pork; and institutionally, prisoners had high pellagra incidence while prison guards, eating outwardly similar food, rarely got sick — the difference being that guards could add meat and milk.

Two key experiments delivered the answer. In the 1915 Rankin Prison experiment, 11 volunteer inmates were fed the local poor-person diet for 6 months — 6 developed pellagra; all recovered after diet improvement. In 1916 Goldberger and team did self-experiments, injecting blood from pellagra patients and applying skin and nasal secretions — no one got sick, directly refuting the contagion hypothesis.

But this evidence was ignored for nearly 20 years, due to racial and class bias — mainstream physicians were reluctant to acknowledge that 'poverty + economy + agricultural policy' caused the disease. Southern monoculture cotton economy used farmland for cotton, and the corn-only diet brought systematic malnutrition — but pellagra was masked by the racialized interpretation that 'Southerners are constitutionally weak'.

In 1937 Elvehjem isolated the chemical structure of niacin; in 1938 the American Medical Association accepted that pellagra equaled nutritional deficiency; from 1942 mandatory niacin flour fortification began, and combined with economic development, US pellagra vanished within 20 years — Goldberger himself didn't live to see it.

This story tells us: nutritional disease is not just a biochemical matter — it intertwines deeply with economics, agriculture, race, and class; 'monoculture staple (corn / white rice / cassava) + poverty' is a disease pattern recurring through history; public health interventions (food fortification) are often more effective than individual supplements.

Modern pellagra still exists: African refugee camps (corn monoculture), parts of arid India, severe alcoholism, Hartnup disease (tryptophan absorption defect), long-term isoniazid therapy (interferes with niacin).

Open this on the map

Chapter 4

NAD+ aging and NMN/NR

Falling NAD+ with age is one of the hottest aging-biology findings of the past decade.

Mechanism: PARP consumes large amounts of NAD+ during the DNA damage response; senescent cells upregulate CD38 (an NAD+-consuming enzyme); and declining mitochondrial function simultaneously reduces NAD+ regeneration.

Precursor supplements: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both metabolic precursors of niacin that can be converted to NAD+ in vivo. NR is a formal niacin form, FDA-recognized as GRAS.

Evidence level (2025): animal model data is strong and consistent (improvements in muscle, cognition, metabolism); human RCT data show NR/NMN do raise blood NAD+, but large RCTs on clinical endpoints (lifespan, strength, cognition) have not yet completed.

Honest bottom line: mechanism is reasonable, safety is good, clinical benefit is pending. This is 'frontier of evidence', not 'proven effective'.

NMN vs NR: practical choice

'Should I buy NMN or NR' is the hottest shopping question in the anti-aging circle. Let's go through the evidence point by point.

Chemistry: NR (nicotinamide riboside) is nicotinamide plus ribose, with a smaller molecular weight; NMN (nicotinamide mononucleotide) is NR plus a phosphate group. In vivo, NMN and NR interconvert via NRK enzymes; both ultimately use the NAMPT → NMN → NAD+ pathway to raise NAD+.

Human RCTs (2018–2024) have been published in multiple iterations:

NR (Trammell 2016, Dollerup 2018, Martens 2018, Conze 2019, Remie 2020): doses 250–1000 mg/day, blood or PBMC NAD+ rose 40–90%, with stable, consistent evidence; clinical endpoints showed mild blood pressure reduction, with muscle strength, insulin sensitivity, and exercise performance mostly null or weakly positiveNMN (Yoshino 2021 in prediabetic women, Yamane 2023 in older adults, Igarashi 2022 in middle-aged men): doses 250–900 mg/day, blood NAD+ rose similarly to NR; clinical endpoints showed slight muscle strength increase and improved gait speed, but small sample sizes and some studies had conflicts of interest
Regulatory status (2025): NR is GRAS at the FDA, a registered supplement (ChromaDex Niagen); NMN had its GRAS status withdrawn by the FDA in 2022 because Metro International filed NMN as a drug IND, and exclusivity rules prevent it from being sold as a dietary supplement — though it still circulates widely, leaving regulation in a gray zone. China has approved NMN for health food since 2020, with looser regulation than the US. The EU classifies both as 'novel food', still under strict approval.

In practice, three options:

Want safety: pick NR (Niagen / Tru Niagen, ChromaDex's patent), regulation is clear, evidence is robust, price is on the high sideWant frontier: NMN prices have dropped to reasonable, but product quality varies dramatically — HPLC testing shows some brands' actual content is less than half the label claimDon't want to spend: nicotinamide (plain B3) can also raise NAD+, very cheap, but it inhibits and is not pathway-equivalent to NR/NMN
The honest conclusion: large long-term RCTs on endpoints like lifespan, falls, and dementia haven't been completed; existing NAD+ data show a reasonable mechanism and good safety but weak clinical endpoints; those impatient for large RCTs can try a small dose (e.g., 300 mg/day), but should know they're betting on the frontier, not 'already proven effective'. Anti-aging interventions with more solid evidence than NMN/NR are actually rather modest: regular resistance + aerobic training, Mediterranean diet, sleep 7–9 hours, social connection, stress management — these are the real drugs that cost $0.

Open this on the map

Chapter 5

High-dose flush and risks

Pharmacologic doses of nicotinic acid (typically 1–3 g/day to treat hyperlipidemia) cause the classic niacin flush: skin reddening, warmth, and itching driven by prostaglandin D2 release, lasting about 30 minutes.

Pharmacologic dosing also carries other risks: hepatotoxicity (especially sustained-release formulations), elevated blood glucose (insulin resistance), elevated uric acid (gout risk), and increased myopathy risk when combined with statins.

By contrast, NMN and NR enter metabolism via nicotinamide rather than the nicotinic acid pathway, so they don't cause flushing, and high-dose hepatic and glucose risks are much lower.

Three contexts should be kept separate: dietary B3, NMN/NR supplementation, and drug-dose nicotinic acid are three different things and cannot be conflated.

Niacin as a lipid drug

The story of nicotinic acid in lipid therapy is a classic case of one drug being gradually displaced by newer ones.

The 1955–2000s were its golden era. Altschul 1955 incidentally discovered that high-dose nicotinic acid lowers cholesterol; subsequent studies confirmed that 1–3 g/day lowers LDL 10–25%, raises HDL 15–35%, lowers TG 20–50%, and lowers 20–30%. The Coronary Drug Project (1986, 15-yr follow-up) showed niacin monotherapy lowered cardiovascular mortality by ~11%. It was one of the few drugs that could substantially raise HDL and lower Lp(a) simultaneously.

In the 2000s, the statin-combination era began eroding its standing. Statins took over the LDL-lowering battle, and niacin retreated to 'supplement when statins are insufficient'. The AIM-HIGH trial (NEJM 2011), comparing niacin + statin to statin alone, showed no additional cardiovascular benefit but more flu-like side effects; HPS2-THRIVE (NEJM 2014, n=25,673) not only showed no benefit but also increased new-onset diabetes, bleeding, and infection. These two large negative trials essentially ended niacin's role as a routine lipid drug.

The reasons for failure aren't hard to understand: once layered on statins, added value was limited; flushing, hepatotoxicity, and glucose effects damaged long-term adherence; new drugs (ezetimibe, PCSK9 inhibitors) offered safer alternatives for LDL reduction.

In 2025 only a few indications remain: hereditary high Lp(a) + extremely high cardiovascular risk (niacin is one of the few oral drugs that can modestly lower Lp(a)); statin intolerance plus a need for further LDL reduction; rare refractory low HDL + high TG. Clinically rare — most physicians haven't prescribed it in years.

For general consumers, one misleading point remains: 'no-flush niacin (nicotinamide / inositol hexanicotinate)' supplements pitch 'niacin benefit without the flush'. But the lipid-lowering action depends on the specific receptor binding of nicotinic acid; changing the form loses that activity, so 'no-flush niacin lowers cholesterol' is marketing — it doesn't actually work.

At the home-use level: buying niacin yourself to lower cholesterol has no evidence base and carries real side-effect risk; true hyperlipidemia typically requires a cardiology evaluation and use of A-level drugs (statins, with ezetimibe or PCSK9 inhibitors as needed) — not something nutritional supplements can handle.

Open this on the map